Xofluza, an oral treatment, was well tolerated in children, said
Roche, whose medicine is already approved broadly in Japan and for
people older than 12 in the United States. The company is seeking to
establish Xofluza as a more-convenient alternative to its older
Tamiflu, which must be taken twice daily for five days and which is
off patent, allowing cheap copies to crowd in.
Xofluza's list price is about $150, while generic Tamiflu, also
called oseltamivir, can cost less.
(Reporting by John Miller; Editing by Michael Shields)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
|